Soarin' Eagle

Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar

Retrieved on: 
Wednesday, May 18, 2022
Risk, DNA, Concentric objects, Computer, General manager, MOU, Public health, U.S. Securities and Exchange Commission, Food, Agriculture, Investment, Synthetic biology, Biosecurity, COVID-19, Marketing, Ginkgo Bioworks, COVID-19 testing, K-12, Plug 1 & Plug 2 Present... First Serve, Airport, Industry, Weather, Infection, Partnership, Soarin' Eagle, Biotechnology, Forward-looking statement, Program, Technology, Travel, Advertising, Map, School, Therapy, SEC, Laboratory, NYSE, Pharmaceutical industry, Vaccine, Ginkgo

BOSTON and DOHA, Qatar, May 18, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and First Serv, a Qatari investment holding company, today announced that they have entered into a non-binding Memorandum of Understanding (MOU) to develop and implement new biosecurity capabilities in Qatar. The partners to the MOU recognize the importance of international collaboration and cooperation to effectively prevent and respond to biological threats in this global age. The initial goal of the partnership is to establish Doha as a critical node of a global pathogen monitoring network, given its important position as a worldwide travel hub. Effective early detection capabilities and sharing of information can empower officials and community leaders to make informed local and global public health decisions.

Key Points: 
  • Effective early detection capabilities and sharing of information can empower officials and community leaders to make informed local and global public health decisions.
  • Ginkgo, through its biosecurity and public health initiative, Concentric by Ginkgo, provides pathogen monitoring capabilities across thousands of sites including schools, airports, and other congregate settings.
  • The partnership with First Serv in Qatar marks a significant milestone in Ginkgo's international expansion as it continues to scale its biosecurity offerings.
  • We are excited about our plans to partner with Ginkgo in support of their market-leading capabilities in this sector.

Ginkgo Bioworks Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 16, 2022
Severe acute respiratory syndrome coronavirus 2, Risk, DNA, Concentric objects, Computer, U.S. Securities and Exchange Commission, Foundry, Annual report, Food, Agriculture, Form 10-K, Synthetic biology, Investor relations, Nature, COVID-19, Total, Adjustment, COVID-19 testing, K-12, Industry, Infection, Partnership, Soarin' Eagle, Biotechnology, Atmosphere, Forward-looking statement, Program, Technology, Sale, Therapy, GAAP, Twitter, Cell, Process control block, Acquisition, Bayer, SEC, Growth, NYSE, CEO, Mobile phone, Pharmaceutical industry, Video game, Animal, Fine chemical, Risk management, Biosecurity, Ginkgo

The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com .

Key Points: 
  • The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com .
  • "We sometimes remark that the pace of change never seems to slow at Ginkgo, and the beginning of 2022 has been no exception," said Jason Kelly, co-founder and CEO of Ginkgo.
  • Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects.
  • In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies.

Evo Foods and Ginkgo Bioworks Announce Partnership to Develop Animal-Free Egg Products

Retrieved on: 
Wednesday, May 11, 2022
COVID-19, Food industry, Forward-looking statement, CDK, Agriculture, CPG, U.S. Securities and Exchange Commission, Taste, PALO, NYSE, Biotechnology, Annual report, K-12, Partnership, Program, Egg, Risk, Synthetic biology, Food, Therapy, DNA, Form 10-K, Biodiversity, Computer, Multimedia, SEC, CEO, Soarin' Eagle, Protein, Technology, Biology, COVID-19 testing, Pharmaceutical industry, Dietary supplement, Ginkgo, Evo

PALO ALTO, Calif. and BOSTON, May 11, 2022 /PRNewswire/ -- Evo Foods, a consumer packaged goods company creating the next generation of plant-based substitutes for animal products, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to develop a method for producing animal-free egg proteins for use in Evo's products.

Key Points: 
  • Evo started in 2020 with the mission to end animal agriculture by creating superior substitutes for animal-derived products by leveraging India's crop biodiversity, starting with the launch of several animal-free egg substitute products.
  • The company recently showcased its products in the U.S. for the first time in San Francisco on April 27, 2022.
  • By collaborating with Ginkgo, Evo intends to create next generation egg substitutes with vastly improved properties.
  • "Evo is committed to playing a part in feeding our ever-growing world, and this partnership will support us as we develop next-generation products in this market."

Ginkgo Bioworks to Expand Platform Capabilities in Agricultural Biologicals and Launch Flagship Partnership with Bayer

Retrieved on: 
Friday, April 22, 2022
Crop protection, Computer, Annual report, Ageing, CEO, Carbon, DNA, Biotechnology, U.S. Securities and Exchange Commission, COVID-19, Nitrogen fixation, Research, R, Group, Program, Risk, Form 10-K, Growth, K-12, Food, COVID-19 testing, Technology, China Biologic Products, Agriculture, Solution, SEC, Forward-looking statement, NYSE, Partnership, Disease, Soarin' Eagle, Therapy, Trust, Synthetic biology, Fine chemical, Pharmaceutical industry, Risk management, Rich Communication Services, Ginkgo, Bayer

Agricultural biologicals are a rapidly growing category of solutions that offer tremendous sustainability and performance benefits.

Key Points: 
  • Agricultural biologicals are a rapidly growing category of solutions that offer tremendous sustainability and performance benefits.
  • While chemical and plant trait solutions have long been the dominant solutions on the market, demand for biologicals has increased dramatically.
  • "Bayer, Ginkgo, and Joyn share a common vision, which is to enable biological products to be a critical part of the solution to the world's greatest agricultural and environmental challenges," said Jason Kelly, CEO and cofounder of Ginkgo Bioworks.
  • Over the last five years, Joyn has developed a new class of microbial solutions in partnership with Bayer and Ginkgo.

GAN Announces Launch of PlayEagle.com by Soaring Eagle Casino & Resort

Retrieved on: 
Monday, April 18, 2022
Software, Lodging, Destinations, Travel, Mobile Entertainment, Technology, Casino, Gaming, Entertainment, Tribe, CEO, Adoption, Soaring Eagle Casino & Resort, Marketing, The iBridge Network, Software, NASDAQ, Database, Private Securities Litigation Reform Act, Apple, IGaming Business, Gambling, Android, Internet, Eagle, Technology, Company, Solution, B2B, GAN, Acquisition, Sport, Soarin' Eagle, IOS, Simulation, Online gambling, Management

GAN Limited (the Company or GAN) (NASDAQ: GAN), a leading North American B2B technology provider of real money internet gaming solutions and a leading International B2C operator of Internet sports betting, today announced the launch of iGaming and online sports betting for Saginaw Chippewa Indian Tribe of Michigan, who own and operate Soaring Eagle Casino & Resort (Soaring Eagle).

Key Points: 
  • GAN Limited (the Company or GAN) (NASDAQ: GAN), a leading North American B2B technology provider of real money internet gaming solutions and a leading International B2C operator of Internet sports betting, today announced the launch of iGaming and online sports betting for Saginaw Chippewa Indian Tribe of Michigan, who own and operate Soaring Eagle Casino & Resort (Soaring Eagle).
  • Soaring Eagle Casino & Resort is the largest casino in the State of Michigan, with an expansive 210,000 square-foot casino facility that offers thousands of slot machines and the widest variety of floor games available in the Midwest.
  • GAN will deploy the Companys patented iBridge Framework to optimally monetize the Soaring Eagle patron database and leverage their on-property retail loyalty program later this year.
  • Dermot S. Smurfit, President & CEO of GAN, noted:
    We are thankful for Soaring Eagles confidence in our B2B platform offering and the opportunity to bring Michigans largest Tribal casino operator online.

Light Bio Partners with Ginkgo Bioworks to Optimize the Brightness of Glowing Plants through Bioluminescence Engineering

Retrieved on: 
Thursday, April 14, 2022
Computer, Annual report, CEO, DNA, Biotechnology, U.S. Securities and Exchange Commission, Plant, COVID-19, Luminescence, Enzyme, Bacteria, Magic, Program, Risk, Engineering, Cell, Form 10-K, Efficiency, K-12, Food, COVID-19 testing, Technology, Agriculture, SEC, Forward-looking statement, NYSE, Biology, Partnership, Soarin' Eagle, Therapy, Synthetic biology, Phosphorus, Pharmaceutical industry, Ginkgo

KETCHUM, Idaho and BOSTON, April 14, 2022 /PRNewswire/ -- Light Bio, Inc., a company that is creating bioluminescent plants for home and garden, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to leverage Ginkgo's plant cell assays for bioluminescence engineering. Through the agreement, Ginkgo aims to help improve the luminescent output and efficiency of the enzymes within Light Bio's glowing ornamental plants.

Key Points: 
  • Through the agreement, Ginkgo aims to help improve the luminescent output and efficiency of the enzymes within Light Bio's glowing ornamental plants.
  • The scientists at Light Bio have discovered a new type of bioluminescence mechanism and are using synthetic biology to engineer plants to efficiently emit light.
  • The original light emission pathway Light Bio uses in its glowing plants comes from bioluminescent mushrooms, and the company is now focused on expanding its engineering capabilities to support the creation of glowing plants.
  • "Light Bio has already achieved strong light emission results on our glowing plant luminescence to date."

FREDsense and Ginkgo Bioworks Announce Partnership to Develop Water Quality Biosensors

Retrieved on: 
Wednesday, April 13, 2022
Water, Computer, Annual report, CEO, DNA, Biotechnology, U.S. Securities and Exchange Commission, COVID-19, Ginkgo Bioworks, Water quality, Program, Risk, Form 10-K, K-12, Food, Technology, COVID-19 testing, Agriculture, Solution, SEC, Forward-looking statement, NYSE, Partnership, Soarin' Eagle, Therapy, Groundwater, Synthetic biology, Oil, Medical imaging, Risk management, Ginkgo

CALGARY, Canada and BOSTON, April 13, 2022 /PRNewswire/ -- FREDsense Technologies Corp, a next generation water quality platform company leveraging synthetic biology to build field kits for faster, cheaper, and more efficient analysis, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to build biosensors for water quality monitoring and detection. Through this partnership, Ginkgo seeks to build four distinct microbial strain biosensors, compatible with FREDsense's field-ready hardware for remote water quality monitoring applications.

Key Points: 
  • Through this partnership, Ginkgo seeks to build four distinct microbial strain biosensors, compatible with FREDsense's field-ready hardware for remote water quality monitoring applications.
  • Water quality has become a growing environmental and public health concern, increasing the demand for scalable monitoring and testing systems.
  • With conventional water quality tests, transporting samples to labs for chemical analysis can lead to lengthy delays in reporting.
  • "Through this partnership with Ginkgo, we aim to introduce rapid, simple and accurate testing to deliver water quality monitoring systems to those that most need it.

Persephone Biosciences and Ginkgo Bioworks Announce Collaboration to Develop Novel Therapeutics

Retrieved on: 
Tuesday, April 12, 2022
Risk, Microbiota, Soarin' Eagle, Form 10-K, Therapy, DNA, Forward-looking statement, Synthetic biology, K-12, NYSE, Annual report, Biotechnology, SEC, Program, Bacteroides, Persephone, CEO, Health, Multi, Agriculture, COVID-19 testing, Technology, U.S. Securities and Exchange Commission, Infant, COVID-19, Gastrointestinal tract, Computer, Animal, SAN, Engineering, Food, Genetic engineering, Partnership, Pharmaceutical industry, Ginkgo

SAN DIEGO and BOSTON, April 12, 2022 /PRNewswire/ -- Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to develop a novel therapeutics based on the bacterial genus Bacteroides.

Key Points: 
  • Ginkgo and Persephone will collaborate on the design and synthesis of such a toolkit as well as the development of novel microbial therapeutic using such tool kit.
  • "We love supporting early-stage biotechs like Persephone to accelerate groundbreaking and meaningful work at its very genesis," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks.
  • "This collaboration not only provides Persephone with critical engineering capabilities, but also sets the stage for us to further partner with Ginkgo, and access its platform's scale, on additional future projects," said Stephanie Culler, co-founder and CEO of Persephone Biosciences.
  • Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery.

Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology

Retrieved on: 
Monday, April 11, 2022
Risk, Business development, Ginkgo Bioworks, Soarin' Eagle, Form 10-K, Therapy, Partnership, Leadership, Synthetic biology, Global Investors Summit, Forward-looking statement, K-12, Environmental health, Interpersonal relationship, NYSE, Annual report, Probiotic, SEC, Veterinarian, Livestock, Program, Environment, Biotechnology, PETS, CEO, Health, U.S. Securities and Exchange Commission, Agriculture, COVID-19 testing, LLC, Technology, Intention, Farmer, Securities Exchange Act of 1934, Ecosystem, Securities Act of 1933, Exchange, COVID-19, Suicidal ideation, Intellectual property, Computer, ELAN, Animal, Viking Global Investors, Disease, North American Pet Health Insurance Association, Security (finance), Dietary supplement, Pharmaceutical industry, Antibiotics, Risk management, Ginkgo, Food, Elanco

GREENFIELD, Ind. and BOSTON, April 11, 2022 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a leading global animal health company, and Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.

Key Points: 
  • and BOSTON, April 11, 2022 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a leading global animal health company, and Ginkgo Bioworks , the leading horizontal platform for cell programming, today announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.
  • By leveraging foundational programs from Elanco, intellectual property from both Elanco and Ginkgo, and an experienced team, BiomEdit should be well positioned as a stand-alone company to develop and launch innovative products to address unmet needs in animal health.
  • "Elanco is excited to continue its participation in the microbiome by partnering with Ginkgo, Viking Global Investors and Anterra Capital to create the next-generation animal health innovation player," said Jeff Simmons, president and CEO of Elanco Animal Health.
  • "Together, we see Ginkgo and BiomEdit addressing significant opportunities in the animal health industry with new breakthroughs based on microbiome science.

Twist Bioscience and Ginkgo Bioworks Sign New Collaboration

Retrieved on: 
Tuesday, April 5, 2022
Data Management, Biotechnology, Technology, Health, Public Relations, Investor Relations, Communications, Other Science, Research, Software, Nanotechnology, Science, Private Securities Litigation Reform Act, Risk, Twist Bioscience, Organization, Soarin' Eagle, Form 10-K, Therapy, NASDAQ, Partnership, DNA, Sale, Investment, Forward-looking statement, Synthetic biology, K-12, Growth, Multimedia, NYSE, Annual report, Martek Biosciences Corporation, Biotechnology, SEC, NGS, Program, Genomics, CEO, U.S. Securities and Exchange Commission, Agriculture, COVID-19 testing, Silicon, Industry, Technology, Biology, CBG, Ecosystem, Doctor of Philosophy, COVID-19, Computer, Drug discovery, Solution, Engineering, Protein, Food, Security (finance), Pharmaceutical industry, Risk management, Ginkgo, GINKGO BIOWORKS, TWIST BIOSCIENCE CORPORATION

The four-year agreement includes an increased commitment by Ginkgo to purchase products from Twist, with the option to access significantly more synthesis capacity to meet Ginkgos anticipated growth.

Key Points: 
  • The four-year agreement includes an increased commitment by Ginkgo to purchase products from Twist, with the option to access significantly more synthesis capacity to meet Ginkgos anticipated growth.
  • View the full release here: https://www.businesswire.com/news/home/20220405005337/en/
    We love to make investments alongside incredible partners like Twist.
  • At Twist, we work in service of our customers, like Ginkgo, who are changing the world for the better, commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist.
  • Together, Twist and Ginkgo facilitate new product development across multiple industries, with Twist supplying the DNA and Ginkgo programming cells.